Clinical trial
Study of BMS-587101 in Patients With Moderate to Severe Psoriasis
NCT00162253 · Bristol-Myers Squibb, Industry · Terminated
Key facts
| NCT number | NCT00162253 |
|---|---|
| Title | Study of BMS-587101 in Patients With Moderate to Severe Psoriasis |
| Official title | Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of BMS-587101 in Patients With Moderate to Severe Psoriasis |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Psoriasis, Moderate to Severe |
| Intervention type | Drug |
| Interventions | BMS 587101 |
| Enrollment | 120 |
| Start date | Apr 1, 2005 |
| Primary completion | Jun 1, 2006 |
| First posted | Sep 13, 2005 |
| Last update posted | Mar 2, 2010 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: